150–166, Etris

A biomaterial derived from porcine intestinal submucosa has been used in the development of a new biologic wound matrix. This review describes the origin of the wound matrix device, including the discovery of the biomaterial and its properties, to the development of the commercial product currently in clinical use. The composition and structure of this biomaterial are described and considered as mechanisms that contribute to its effectiveness in wound management. The wound matrix developed from this unique biomaterial was evaluated in a pilot study of human partial-thickness dermal wounds and was found to be beneficial, especially in its dehydrated form. Other applications of this biomaterial, as well as its limitations, are also discussed. A New Biomaterial Derived from Small Intestine Submucosa and Developed into a Wound Matrix Device Marie Brown-Etris, RN, CWOCN; William D. Cutshall, MD; Michael C. Hiles, PhD From Etris Associates, Inc., Philadelphia, Pennsylvania; Bloomington, Indiana; and Cook Biotech Inc., West Lafayette, Indiana Disclosure: This study was supported by a study grant from Cook Biotech, Inc., West Lafayette, Indiana. Dr. Hiles has partial ownership in patents related to the subject matter of this manuscript and is employed by the company that manufactures the biomaterial. WOUNDS 2002;14(4):150–166 Address correspondence to: Marie Brown-Etris, RN, CWOCN, Etris Associates Inc., 14450 Bustleton Ave., Philadelphia, PA 19116 Phone: (215) 673-3600; Fax (215)673-9892; E-mail: [email protected] B DO NO T D UP LI CA TE